RVMD

Dollar change -1.50
Percentage change -3.23	%

Peers: AMGN GILD VRTX BMY MRNA PFE REGN ILMN BIIB EXEL

| Held by: VTI IWM VB VXF VBK XBI IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.59	Insider Own	16.18%	Shs Outstand	167.75M	Perf Week	-5.01%
Market Cap	8.19B	Forward P/E	-	EPS next Y	-3.97	Insider Trans	3.16%	Shs Float	151.65M	Perf Month	-24.27%
Income	-567.06M	PEG	-	EPS next Q	-0.99	Inst Own	81.75%	Short Float	10.65%	Perf Quarter	2.81%
Sales	0.74M	P/S	11071.59	EPS this Y	9.81%	Inst Trans	1.51%	Short Ratio	10.45	Perf Half Y	13.06%
Book/sh	9.34	P/B	4.81	EPS next Y	-14.13%	ROA	-41.28%	Short Interest	16.16M	Perf Year	81.68%
Cash/sh	8.50	P/C	5.29	EPS next 5Y	-	ROE	-47.18%	52W Range	23.51 - 62.40	Perf YTD	56.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-36.05%	ROI	-34.48%	52W High	-28.00%	Beta	1.41
Dividend TTM	-	Quick Ratio	14.24	Sales past 5Y	11.11%	Gross Margin	-1420.89%	52W Low	91.11%	ATR (14)	2.34
Dividend Ex-Date	-	Current Ratio	14.24	EPS Y/Y TTM	-10.04%	Oper. Margin	-88031.94%	RSI (14)	29.03	Volatility	3.38% 4.17%
Employees	378	Debt/Eq	0.06	Sales Y/Y TTM	-97.16%	Profit Margin	-76423.32%	Recom	1.07	Target Price	73.62
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	5.64%	Payout	-	Rel Volume	0.84	Prev Close	46.43
Sales Surprise	-100.00%	EPS Surprise	-5.24%	Sales Q/Q	-	Earnings	Nov 06 AMC	Avg Volume	1.55M	Price	44.93
SMA20	-14.88%	SMA50	-13.89%	SMA200	5.73%	Trades		Volume	1,302,478	Change	-3.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-16-24	Reiterated	Needham	Buy	$46 → $62
Jul-12-24	Initiated	Barclays	Overweight	$52
Jul-08-24	Initiated	Jefferies	Buy	$63
Apr-12-24	Reiterated	Needham	Buy	$36 → $46
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy	$36 → $48
Mar-11-24	Initiated	Piper Sandler	Overweight	$43
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy	$31 → $34
Jan-04-24	Initiated	Wedbush	Outperform	$41
Nov-16-23	Initiated	Raymond James	Outperform	$30
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight	$32 → $38
Dec-14-22	Initiated	Needham	Buy	$31
Oct-21-22	Initiated	Oppenheimer	Outperform	$30
May-20-22	Initiated	BofA Securities	Neutral	$24
Mar-01-22	Upgrade	Stifel	Hold → Buy	$36 → $26
Sep-23-21	Initiated	Stifel	Hold	$34
Aug-12-21	Downgrade	Goldman	Buy → Neutral	$49 → $27
May-18-21	Initiated	Goldman	Buy	$49
May-21-20	Initiated	H.C. Wainwright	Buy	$55
Mar-09-20	Initiated	JP Morgan	Neutral	$32
Mar-09-20	Initiated	Guggenheim	Buy	$50

Show Previous Ratings

Dec-05-24 04:05PM	Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-04-24 06:51AM	Revolution Medicines price target raised to $87 from $82 at Guggenheim (TipRanks)
Dec-03-24 10:38PM	Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -6.89%
Dec-02-24 04:31PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire) -10.46%
07:30AM	Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio (GlobeNewswire)
04:05PM	Loading…
Nov-27-24 04:05PM	Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 (GlobeNewswire)
Nov-06-24 04:02PM	Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-05-24 09:00AM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-24 04:05PM	Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 (GlobeNewswire) +5.94%
Oct-25-24 04:15AM	Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Oct-23-24 06:00AM	Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Oct-21-24 04:05PM	Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -5.31%
Oct-07-24 09:00AM	Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast (GlobeNewswire)
Aug-07-24 04:05PM	Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
Jul-31-24 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024 (GlobeNewswire)
12:00PM	Loading…
Jul-11-24 12:00PM	Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer (GlobeNewswire)
Jul-10-24 05:58AM	Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last? (Zacks)
Jul-08-24 04:05PM	Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024 (GlobeNewswire) +5.46% +10.97%
Jun-08-24 09:00AM	The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024 (InvestorPlace)
Jun-05-24 04:05PM	Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-09-24 03:41PM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 09:58PM	RVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024 (InvestorPlace)
04:02PM	Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-01-24 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 (GlobeNewswire)
Apr-09-24 03:34PM	Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-08-24 11:36AM	Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-04-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-28-24 04:05PM	Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Feb-26-24 05:20PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-20-24 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 (GlobeNewswire)
Feb-01-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-17-24 09:55AM	Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High? (Zacks)
Jan-04-24 07:00AM	Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-09-23 09:10AM	Revolution Medicines Completes Acquisition of EQRx (GlobeNewswire) -5.48%
Nov-08-23 11:30AM	Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition (GlobeNewswire)
Nov-07-23 10:14AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:55PM	Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:05PM	Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-01-23 07:00AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote FOR Proposed Acquisition of EQRx, Inc. (GlobeNewswire)
Oct-31-23 04:15PM	Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023 (GlobeNewswire) +7.90%
Oct-23-23 04:06PM	Revolution Crashes 34% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining. (Investor's Business Daily) -34.38% +14.52%
01:48PM	Rebel's Edge - October 20: $TGH, $RVMD, and Astros VS Rangers (TheStreet.com)
12:04PM	Why Revolution Medicines Stock Is Crashing Today (Motley Fool)
10:07AM	Revolution Medicines Crashes 39% On Lackluster Test Results In Cancer Treatment (Investor's Business Daily)
Oct-22-23 02:30AM	Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 (GlobeNewswire)
Oct-19-23 07:02AM	Insider Sell: COO Margaret Horn Sells 25,000 Shares of Revolution Medicines Inc (GuruFocus.com)
Oct-16-23 03:19PM	Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 (Investor's Business Daily) +14.08%
09:45AM	Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-13-23 02:54PM	Why Shares of Revolution Medicines Were Popping on Friday (Motley Fool) +23.60%
11:50AM	Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting (GlobeNewswire)
Oct-04-23 04:05PM	Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast (GlobeNewswire)
Sep-20-23 07:01AM	Insider Sell: COO Margaret Horn Sells 7,514 Shares of Revolution Medicines Inc (RVMD) (GuruFocus.com)
Sep-19-23 07:00AM	Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor (GlobeNewswire)
Aug-17-23 04:05PM	Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins (GlobeNewswire)
Aug-09-23 02:13PM	Industry Analysts Just Made A Sizeable Upgrade To Their Revolution Medicines, Inc. (NASDAQ:RVMD) Revenue Forecasts (Simply Wall St.)
Aug-08-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Aug-03-23 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023 (GlobeNewswire)
Aug-01-23 02:34PM	EQRx sells to another Alexis Borisy biotech after multiple pivots (American City Business Journals) +20.00%
07:00AM	Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital (GlobeNewswire)
Jul-06-23 09:59AM	Revolution Medicines Insider Ups Holding During Year (Simply Wall St.)
Jun-09-23 08:29AM	We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate (Simply Wall St.)
Jun-08-23 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.69%
May-24-23 04:05PM	Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit (GlobeNewswire)
May-13-23 08:19AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25% (Simply Wall St.)
May-10-23 06:10AM	Revolution Medicines First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-09-23 09:40AM	Q1 2023 Revolution Medicines Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:25PM	Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:55AM	Wall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a Bet (Zacks)
May-01-23 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 (GlobeNewswire)
10:01AM	Revolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-19-23 07:15AM	Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns climbed after last week's 16% gain, institutional investors must be happy (Simply Wall St.)
Apr-13-23 04:05PM	Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference (GlobeNewswire) +7.83%
Apr-06-23 07:00AM	Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-22-23 11:29AM	Revolution Medicines (NASDAQ:RVMD investor three-year losses grow to 18% as the stock sheds US$171m this past week (Simply Wall St.)
Mar-11-23 03:27AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 04:02PM	Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.71%
Mar-02-23 09:15PM	Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock (GlobeNewswire) -11.72% +8.78%
Mar-01-23 04:17PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
Feb-27-23 06:25PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +9.81%
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-21-23 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023 (GlobeNewswire)
Feb-02-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice (Zacks)
07:00AM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-23-23 05:31AM	Insiders sitting comfortably on a US$376k profit after buying Revolution Medicines, Inc. (NASDAQ:RVMD) stock worth US$1.0m last year (Simply Wall St.)
Jan-12-23 03:25AM	Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength? (Zacks) +11.12%
Jan-03-23 07:00AM	Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-22 06:15AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-26-22 08:14AM	We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely (Simply Wall St.)
Dec-19-22 07:00AM	Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor (GlobeNewswire) -9.42%
Dec-08-22 06:19AM	Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration (Benzinga)
Dec-07-22 04:05PM	Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofis Termination of SHP2 Inhibitor Development and Commercialization Collaboration (GlobeNewswire)
Nov-10-22 05:48AM	Institutional owners may consider drastic measures as Revolution Medicines, Inc.'s (NASDAQ:RVMD) recent US$110m drop adds to long-term losses (Simply Wall St.) +13.34%
Nov-09-22 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-22 05:55PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates (Zacks)

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schroeder Thilo	Director	Dec 05 '24	Buy	46.00	1,304,347	59,999,962	2,096,612	Dec 09 04:15 PM
Cislini Jeff	General Counsel	Nov 15 '24	Sale	55.13	2,554	140,811	43,080	Nov 19 04:05 PM
JEFFREY TODD CISLINI	Officer	Nov 15 '24	Proposed Sale	57.37	2,554	146,523		Nov 15 04:44 PM
Kelsey Stephen Michael	See Remarks	Nov 13 '24	Option Exercise	4.09	16,666	68,164	281,074	Nov 15 04:08 PM
Kelsey Stephen Michael	See Remarks	Nov 13 '24	Sale	58.65	16,666	977,509	264,408	Nov 15 04:08 PM
STEPHEN M. KELSEY	Officer	Nov 13 '24	Proposed Sale	59.33	16,666	988,794		Nov 13 04:30 PM
Cislini Jeff	General Counsel	Nov 06 '24	Option Exercise	36.57	6,000	219,420	51,634	Nov 08 04:20 PM
Cislini Jeff	General Counsel	Nov 06 '24	Sale	60.00	6,000	360,000	45,634	Nov 08 04:20 PM
JEFFREY TODD CISLINI	Officer	Nov 06 '24	Proposed Sale	56.75	6,000	340,500		Nov 06 05:07 PM
GOLDSMITH MARK A	See Remarks	Nov 04 '24	Option Exercise	2.58	87,500	226,115	351,070	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 01 '24	Option Exercise	4.09	9,100	37,219	309,270	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 04 '24	Sale	55.56	50,900	2,827,821	300,170	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 01 '24	Sale	55.02	10,000	550,238	20,424	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 01 '24	Sale	55.02	9,100	500,714	300,170	Nov 05 04:21 PM
Patel Sushil	Director	Oct 31 '24	Option Exercise	24.84	5,000	124,200	24,948	Nov 04 04:05 PM
Patel Sushil	Director	Oct 31 '24	Sale	54.14	5,000	270,714	19,948	Nov 04 04:05 PM
REBECCA EVE GOLDSMITH TR U/A D	Director	Nov 01 '24	Proposed Sale	53.50	5,000	267,500		Nov 01 04:43 PM
J H GOLDSMITH & M A GOLDSMITH	Director	Nov 01 '24	Proposed Sale	53.50	5,000	267,500		Nov 01 04:42 PM
MARK A GOLDSMITH	Director	Nov 01 '24	Proposed Sale	53.50	60,000	3,210,000		Nov 01 04:42 PM
SUSHIL PATEL	Director	Oct 31 '24	Proposed Sale	50.50	5,000	252,500		Oct 31 04:30 PM
Kelsey Stephen Michael	See Remarks	Oct 14 '24	Option Exercise	4.09	16,666	68,164	281,074	Oct 16 04:07 PM
Kelsey Stephen Michael	See Remarks	Oct 14 '24	Sale	49.49	16,666	824,804	264,408	Oct 16 04:07 PM
Horn Margaret A	Chief Operating Officer	Oct 11 '24	Option Exercise	4.09	50,000	204,500	182,320	Oct 15 05:31 PM
Horn Margaret A	Chief Operating Officer	Oct 11 '24	Sale	50.34	50,000	2,517,055	132,320	Oct 15 05:31 PM
GOLDSMITH MARK A	See Remarks	Oct 11 '24	Option Exercise	4.09	30,000	122,700	330,170	Oct 15 05:30 PM
GOLDSMITH MARK A	See Remarks	Oct 11 '24	Sale	50.36	30,000	1,510,773	300,170	Oct 15 05:30 PM
Anders Jack	Chief Financial Officer	Oct 11 '24	Option Exercise	2.68	10,000	26,800	108,932	Oct 15 05:30 PM
Anders Jack	Chief Financial Officer	Oct 11 '24	Sale	50.30	10,000	502,979	98,932	Oct 15 05:30 PM
Cislini Jeff	General Counsel	Oct 11 '24	Option Exercise	36.57	6,000	219,420	51,634	Oct 15 05:29 PM
Cislini Jeff	General Counsel	Oct 11 '24	Sale	50.17	6,000	301,027	45,634	Oct 15 05:29 PM
STEPHEN M. KELSEY	Officer	Oct 14 '24	Proposed Sale	50.48	16,666	841,300		Oct 15 08:03 AM
MARK A GOLDSMITH	Director	Oct 11 '24	Proposed Sale	49.50	30,000	1,485,000		Oct 11 04:22 PM
JEFFREY TODD CISLINI	Officer	Oct 11 '24	Proposed Sale	49.50	6,000	297,000		Oct 11 04:21 PM
JACK LEE ANDERS	Officer	Oct 11 '24	Proposed Sale	49.50	10,000	495,000		Oct 11 04:21 PM
MARGARET A HORN	Officer	Oct 11 '24	Proposed Sale	49.50	50,000	2,475,000		Oct 11 04:21 PM
Weber Barbara	Director	Oct 08 '24	Sale	48.02	5,200	249,716	13,065	Oct 10 04:16 PM
BARBARA L WEBER	Director	Oct 08 '24	Proposed Sale	47.34	5,200	246,168		Oct 08 04:23 PM
GOLDSMITH MARK A	See Remarks	Oct 01 '24	Option Exercise	4.09	10,000	40,900	310,170	Oct 03 04:33 PM
GOLDSMITH MARK A	See Remarks	Oct 01 '24	Sale	44.93	10,000	449,322	300,170	Oct 03 04:33 PM
MARK A GOLDSMITH	Director	Oct 01 '24	Proposed Sale	45.35	10,000	453,500		Oct 01 04:33 PM
Anders Jack	Chief Financial Officer	Sep 16 '24	Sale	44.19	2,244	99,152	98,932	Sep 18 04:18 PM
GOLDSMITH MARK A	See Remarks	Sep 16 '24	Sale	44.19	11,715	517,631	300,170	Sep 18 04:18 PM
Horn Margaret A	Chief Operating Officer	Sep 16 '24	Sale	44.19	4,331	191,367	132,320	Sep 18 04:17 PM
Kelsey Stephen Michael	See Remarks	Sep 16 '24	Sale	44.19	4,665	206,124	264,408	Sep 18 04:17 PM
Cislini Jeff	General Counsel	Sep 16 '24	Sale	44.19	1,454	64,245	45,634	Sep 18 04:16 PM
Anders Jack	Officer	Sep 16 '24	Proposed Sale	42.12	1,832	77,164		Sep 16 07:06 PM
Kelsey Stephen Michael	Officer	Sep 16 '24	Proposed Sale	42.12	4,601	193,794		Sep 16 06:41 PM
Horn Margaret A	Officer	Sep 16 '24	Proposed Sale	42.12	4,271	179,895		Sep 16 06:22 PM
Cislini Jeff	Officer	Sep 16 '24	Proposed Sale	42.12	1,433	60,358		Sep 16 05:37 PM
Anders Jack	Officer	Sep 16 '24	Proposed Sale	42.12	1,832	77,164		Sep 16 05:24 PM
GOLDSMITH MARK A	Officer	Sep 16 '24	Proposed Sale	42.12	11,561	486,949		Sep 16 05:15 PM
Kelsey Stephen Michael	See Remarks	Sep 13 '24	Option Exercise	4.09	16,667	68,168	285,740	Sep 16 04:05 PM
Kelsey Stephen Michael	See Remarks	Sep 13 '24	Sale	43.32	16,667	722,087	269,073	Sep 16 04:05 PM
STEPHEN M. KELSEY	Officer	Sep 13 '24	Proposed Sale	41.97	16,667	699,514		Sep 13 04:23 PM
BARBARA L WEBER	Officer	Aug 21 '24	Proposed Sale	44.83	1,808	81,053		Aug 21 04:14 PM
Kelsey Stephen Michael	See Remarks	Aug 13 '24	Option Exercise	4.09	16,667	68,168	285,740	Aug 15 04:48 PM
Kelsey Stephen Michael	See Remarks	Aug 13 '24	Sale	42.98	16,667	716,389	269,073	Aug 15 04:48 PM
STEPHEN M. KELSEY	Officer	Aug 13 '24	Proposed Sale	42.98	16,667	716,348		Aug 13 04:25 PM
GOLDSMITH MARK A	See Remarks	Aug 01 '24	Option Exercise	4.09	10,000	40,900	321,885	Aug 02 05:35 PM
GOLDSMITH MARK A	See Remarks	Aug 01 '24	Sale	45.88	10,000	458,827	311,885	Aug 02 05:35 PM
MARK A GOLDSMITH	Director	Aug 01 '24	Proposed Sale	45.64	10,000	456,400		Aug 01 04:29 PM
Kelsey Stephen Michael	See Remarks	Jul 15 '24	Option Exercise	4.09	16,667	68,168	285,740	Jul 17 04:07 PM
Kelsey Stephen Michael	See Remarks	Jul 15 '24	Sale	46.47	16,667	774,516	269,073	Jul 17 04:07 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Option Exercise	4.09	25,000	102,250	336,885	Jul 16 05:05 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Sale	45.05	25,000	1,126,205	311,885	Jul 16 05:05 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Sale	45.01	10,000	450,117	25,424	Jul 16 05:05 PM
Cislini Jeff	General Counsel	Jul 09 '24	Sale	40.83	2,399	97,951	47,088	Jul 10 04:36 PM
Patel Sushil	Director	Jul 09 '24	Option Exercise	16.80	2,155	36,204	22,103	Jul 10 04:36 PM
Patel Sushil	Director	Jul 09 '24	Sale	44.00	2,155	94,820	19,948	Jul 10 04:36 PM
Cislini Jeff	General Counsel	Jun 26 '24	Sale	38.47	2,000	76,940	49,487	Jun 27 06:48 PM
Kelsey Stephen Michael	See Remarks	Jun 25 '24	Option Exercise	4.09	16,467	67,350	285,540	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 24 '24	Option Exercise	4.09	200	818	269,273	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 25 '24	Sale	39.06	16,467	643,152	269,073	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 24 '24	Sale	39.00	200	7,800	269,073	Jun 26 04:26 PM
GOLDSMITH MARK A	See Remarks	Jun 17 '24	Sale	37.39	11,950	446,770	311,885	Jun 20 04:14 PM
Anders Jack	Chief Financial Officer	Jun 17 '24	Sale	37.39	1,893	70,775	101,176	Jun 20 04:13 PM
Horn Margaret A	Chief Operating Officer	Jun 17 '24	Sale	37.39	4,415	165,064	136,651	Jun 20 04:12 PM
Kelsey Stephen Michael	See Remarks	Jun 17 '24	Sale	37.39	3,349	125,209	269,073	Jun 20 04:11 PM
Cislini Jeff	General Counsel	Jun 17 '24	Sale	37.39	1,757	65,690	51,487	Jun 20 04:11 PM
Wei Lin	Chief Medical Officer	Jun 17 '24	Sale	37.39	5,589	208,954	70,851	Jun 20 04:10 PM
GOLDSMITH MARK A	See Remarks	Jun 03 '24	Option Exercise	4.09	7,500	30,675	329,822	Jun 05 04:18 PM
GOLDSMITH MARK A	See Remarks	Jun 03 '24	Sale	39.99	7,500	299,942	322,322	Jun 05 04:18 PM
Cislini Jeff	General Counsel	May 21 '24	Sale	39.11	1,500	58,671	52,874	May 22 04:11 PM
Anders Jack	Chief Financial Officer	May 03 '24	Option Exercise	2.68	10,000	26,800	111,959	May 03 07:36 PM
Anders Jack	Chief Financial Officer	May 03 '24	Sale	40.03	10,000	400,260	101,959	May 03 07:36 PM
GOLDSMITH MARK A	See Remarks	Apr 10 '24	Sale	35.33	10,000	353,346	30,424	Apr 12 08:08 PM
GOLDSMITH MARK A	See Remarks	Apr 10 '24	Sale	35.48	7,500	266,122	452,879	Apr 12 08:08 PM
Patel Sushil	Director	Apr 10 '24	Option Exercise	16.80	2,155	36,204	17,855	Apr 12 04:23 PM
Patel Sushil	Director	Apr 10 '24	Sale	37.00	2,155	79,735	15,700	Apr 12 04:23 PM
Cislini Jeff	General Counsel	Mar 27 '24	Sale	30.99	1,500	46,481	54,374	Mar 28 04:11 PM
Cislini Jeff	General Counsel	Mar 18 '24	Sale	31.58	1,252	39,542	55,874	Mar 20 04:45 PM
Kelsey Stephen Michael	See Remarks	Mar 18 '24	Sale	31.58	2,123	67,051	270,909	Mar 20 04:45 PM
Horn Margaret A	Chief Operating Officer	Mar 18 '24	Sale	31.58	2,914	92,033	139,553	Mar 20 04:44 PM
GOLDSMITH MARK A	See Remarks	Mar 18 '24	Sale	31.58	5,788	182,804	460,379	Mar 20 04:44 PM
Anders Jack	Chief Financial Officer	Mar 18 '24	Sale	31.58	1,261	39,826	101,959	Mar 20 04:43 PM
Horn Margaret A	Chief Operating Officer	Mar 11 '24	Option Exercise	4.09	15,735	64,356	158,202	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 12 '24	Option Exercise	4.09	7,936	32,458	150,403	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 11 '24	Sale	34.02	15,735	535,306	142,467	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 12 '24	Sale	34.07	7,936	270,345	142,467	Mar 13 04:32 PM
Cislini Jeff	General Counsel	Jan 22 '24	Sale	27.00	1,500	40,500	36,126	Jan 24 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Revolution Medicines Inc

Upgrade your FINVIZ experience